ReviewInternational journal of nanomedicine2026
Engineered Exosomes: Advances in Therapeutic Applications for Otolaryngology-Head and Neck Diseases.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- The Role of Exosomes in Bone Metastasis and Bone Tissue Engineering: Molecular Mechanisms and Therapeutic Opportunities.Biotechnology journal · 2026Review
- Therapeutic Mechanisms of Stem Cell-Derived Exosomes for Neurological Disorders: An Overview.Molecular neurobiology · 2026Review
- Decoding the role of exosomes in bladder cancer: focusing on tumor progression and immune microenvironment modulation.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given the intricate anatomy of otolaryngology-head and neck (OHNS) regions and the inherent limitations of conventional therapies, many OHNS diseases have suboptimal clinical outcomes. As natural intercellular mediators, exosomes have demonstrated unique application potential in OHNS treatment in recent years, thanks to their high biocompatibility, low immunogenicity, and intrinsic targeting capabilities. However, such issues as limited drug-loading capacity, suboptimal in vivo stability, and insufficient targeting precision still hinder their clinical translation. Notably, recent advances in engineering strategies such as genetic editing, surface modification, and optimized drug loading enhance natural exosomes' functionality, boosting targeting accuracy, in vivo stability, and therapeutic efficacy. Considering conventional therapy limitations and engineered exosomes' unique potential, this review synthesizes their progress, mechanisms, and translational challenges in OHNS, and addresses lingering technical and translation barriers via interdisciplinary collaboration to optimize their design, utility, and bench-to-bedside translation, as these exosomes are promising precision tools for refractory OHNS diseases advancing precision medicine in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.